Complement Inactivating Agents
- Complement Inactivating Agents
- Accession Number
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
Drug Drug Description Eculizumab A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Icatibant A bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE). Human C1-esterase inhibitor A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema. Nafamostat Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement... Ravulizumab A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. Pegcetacoplan A complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Vilobelimab An antibody directed against anti-human complement factor 5a is used to treat COVID-19 in adults for emergency use. Fasitibant Fasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee). Avacincaptad pegol An RNA aptamer inhibiting the complement C5 indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. Pozelimab A human monoclonal IgG4 antibody used to treat CD55-deficient protein-losing enteropathy (PLE) or CHAPLE disease Zilucoplan A complement inhibitor used to treat generalized myasthenia gravis in anti-acetylcholine receptor (AChR) antibody-positive adults.
- Drugs & Drug Targets